Correlation Between Morgan Stanley and Hemogenyx Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Morgan Stanley and Hemogenyx Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Morgan Stanley and Hemogenyx Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Morgan Stanley Direct and Hemogenyx Pharmaceuticals PLC, you can compare the effects of market volatilities on Morgan Stanley and Hemogenyx Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Morgan Stanley with a short position of Hemogenyx Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Morgan Stanley and Hemogenyx Pharmaceuticals.

Diversification Opportunities for Morgan Stanley and Hemogenyx Pharmaceuticals

-0.71
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Morgan and Hemogenyx is -0.71. Overlapping area represents the amount of risk that can be diversified away by holding Morgan Stanley Direct and Hemogenyx Pharmaceuticals PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Hemogenyx Pharmaceuticals and Morgan Stanley is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Morgan Stanley Direct are associated (or correlated) with Hemogenyx Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Hemogenyx Pharmaceuticals has no effect on the direction of Morgan Stanley i.e., Morgan Stanley and Hemogenyx Pharmaceuticals go up and down completely randomly.

Pair Corralation between Morgan Stanley and Hemogenyx Pharmaceuticals

Given the investment horizon of 90 days Morgan Stanley Direct is expected to generate 0.15 times more return on investment than Hemogenyx Pharmaceuticals. However, Morgan Stanley Direct is 6.54 times less risky than Hemogenyx Pharmaceuticals. It trades about 0.09 of its potential returns per unit of risk. Hemogenyx Pharmaceuticals PLC is currently generating about -0.16 per unit of risk. If you would invest  2,043  in Morgan Stanley Direct on September 23, 2024 and sell it today you would earn a total of  41.00  from holding Morgan Stanley Direct or generate 2.01% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy95.45%
ValuesDaily Returns

Morgan Stanley Direct  vs.  Hemogenyx Pharmaceuticals PLC

 Performance 
       Timeline  
Morgan Stanley Direct 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Morgan Stanley Direct are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite quite inconsistent fundamental indicators, Morgan Stanley may actually be approaching a critical reversion point that can send shares even higher in January 2025.
Hemogenyx Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Hemogenyx Pharmaceuticals PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Morgan Stanley and Hemogenyx Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Morgan Stanley and Hemogenyx Pharmaceuticals

The main advantage of trading using opposite Morgan Stanley and Hemogenyx Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Morgan Stanley position performs unexpectedly, Hemogenyx Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hemogenyx Pharmaceuticals will offset losses from the drop in Hemogenyx Pharmaceuticals' long position.
The idea behind Morgan Stanley Direct and Hemogenyx Pharmaceuticals PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Other Complementary Tools

Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios